Clinical trial · Observational
Bevacizumab Versus Docetaxel/Erlotinib on Tumor Metrics in Patients With Previously Untreated Advanced Non Small Cell Lung Cancer
Impact of Bevacizumab Versus Docetaxel/Erlotinib on Tumor Metrics in Patients With Previously Untreated Advanced Non Small Cell Lung Cancer: A Study by the Hellenic Co-operative Oncology Group
NCT04257864CI-TRIAL-00043304completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To determine the more effective dosing sequence of intermittent erlotinib and docetaxel for treating patients with the diagnosis of advanced Non-Small-Lung-Cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non Small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (3)
- label
- Erlotinib followed by docetaxel
- description
- Erlotinib given for twelve consecutive days before docetaxel
- label
- Docetaxel followed by erlotinib
- description
- Erlotinib given for twelve consecutive days after docetaxel
- label
- Bevacizumab treated
- description
- Bevacizumab treated patients
Primary outcomes (1)
- measure
- Tumor response
- timeFrame
- Every 12 -16 weeks
- description
- Evaluation of response using RECIST 1.1 criteria (REF) was based on the measurement of a total of 5 measurable lesions.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: 1. Male and female patients aged 18 to 75 years inclusive, with histologically confirmed metastatic non small cell lung cancer will be enrolled. 2. Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 1. 3. Presence of measurable or evaluable disease (lesions that are present but do not fulfil the criteria for measurable disease). Exclusion Criteria: 1\. Patients who have undergone complete tumor resection after responding to platinum based chemotherapy.
References
Publications (0)
Data not yet available
No reference posted for this study.